Cancer Family
Urinary System Neoplasm
CI-CAN-00000379Explore in graph →
Non-malignant964 active trials28 approved drugs109 evidence items
- NCIt
- C3431
Loading cancer entity…
Cancer Family
CI-CAN-00000379Explore in graph →
Clinical trials
4,238 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05785039 | A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors | recruiting | Phase 2 | 76 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06582017 | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | recruiting | Phase 1 | 100 | Nammi Therapeutics IncINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07660055 | Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors | recruiting | Phase 1 | 156 | Novartis PharmaceuticalsINDUSTRY | 4 | Aug 27, 2026 | clinicaltrials |
| NCT07789119 | Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma And Related Malignancies Of The Urinary Tract | not yet recruiting | — | 50,000 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04681690 | German National Registry for NSS | terminated | — | 137 | Association of Urologic Oncology (AUO)OTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07180121 | Information Needs and Supportive Rehabilitation Over Time in Patients Undergoing Cystectomy in Bladder Cancer(CaRe) | enrolling by invitation | — | 200 | Linkoeping UniversityOTHER_GOV | 1 | Aug 26, 2026 | clinicaltrials |
| NCT01216371 | Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)(SMAT) | terminated | Phase 2 | 60 | Association of Urologic Oncology (AUO)OTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT02402244 | Project: Every Child for Younger Patients With Cancer | recruiting | — | 75,000 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT03258593 | Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04322318 | A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | recruiting | Phase 2 | 256 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT04670445 | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer(UPLIFT) | completed | N/A | 199 | Massachusetts General HospitalOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06401330 | A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | recruiting | Phase 3 | 1,656 | Children's Oncology GroupNETWORK | 4 | Aug 25, 2026 | clinicaltrials |
| NCT06414317 | An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers | active not recruiting | N/A | 12 | Roswell Park Cancer InstituteOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07579195 | Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial | recruiting | Phase 1 / Phase 2 | 12 | University of WashingtonOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07783815 | A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG Failure | not yet recruiting | Phase 1 | 20 | Xiangya Hospital of Central South UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT00001238 | Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders | recruiting | — | 5,000 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT00902590 | A Genotype-Phenotype Urothelial Cancer Registry | active not recruiting | — | 3,519 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03141177 | A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(CheckMate 9ER) | completed | Phase 3 | 701 | Bristol-Myers SquibbINDUSTRY | 18 | Aug 24, 2026 | clinicaltrials |
| NCT03185468 | Intervention of Bladder Cancer by CAR-T | terminated | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07781956 | Home-Based Supportive Care Program for NMIBC Patients Receiving Intravesical Perfusion: Construction and Preliminary Application(NMIBC-HSC) | not yet recruiting | N/A | 40 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04147494 | Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues | active not recruiting | Early Phase 1 | 29 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04579380 | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | active not recruiting | Phase 2 | 217 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 8 | Aug 21, 2026 | clinicaltrials |
| NCT06432036 | Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial | recruiting | Phase 1 / Phase 2 | 25 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06862219 | A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer | recruiting | Phase 4 | 100 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07480356 | Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer(ADVANCED-3) | recruiting | Phase 3 | 284 | Protara TherapeuticsINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 299 | Huahui HealthINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT03274258 | Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma | terminated | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04410302 | Patient-Derived Xenografts to Reduce Cancer Health Disparities | recruiting | — | 500 | University of California, DavisOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04473781 | Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer | terminated | Phase 1 | 2 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05468697 | A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) | active not recruiting | Phase 1 / Phase 2 | 60 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Aug 20, 2026 | clinicaltrials |
| NCT05614739 | FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3(FORAGER-1) | recruiting | Phase 1 | 677 | Eli Lilly and CompanyINDUSTRY | 14 | Aug 20, 2026 | clinicaltrials |
| NCT06940518 | Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07123090 | A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma(SPARCC) | recruiting | Phase 2 | 25 | Stephanie BergOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07129993 | Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma | recruiting | Phase 2 / Phase 3 | 630 | Daiichi SankyoINDUSTRY | 7 | Aug 20, 2026 | clinicaltrials |
| NCT07187778 | Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE) | recruiting | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07227077 | Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial | recruiting | N/A | 50 | Medical College of WisconsinOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07714018 | Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance | recruiting | N/A | 20 | Roswell Park Cancer InstituteOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07776483 | Personalized ctDNA Monitoring for Predicting Immunotherapy Outcomes in Advanced Non-Clear Cell Renal Cell Carcinoma | not yet recruiting | — | 67 | West China HospitalOTHER | 0 | Aug 20, 2026 | clinicaltrials |
| NCT07776717 | TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma(TACTIC-RCC) | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 0 | Aug 20, 2026 | clinicaltrials |
| NCT03193970 | Measuring Surgical Recovery After Radical Cystectomy | recruiting | — | 2,000 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04788095 | App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal Cell Cancer | active not recruiting | N/A | 21 | City of Hope Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05361720 | Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study | recruiting | Phase 2 | 54 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06059547 | Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer | completed | Phase 2 | 31 | CatalYm GmbHINDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | AstraZenecaINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT02609269 | Decipher Genomics Resource for Intelligent Discovery(GRID®) | enrolling by invitation | — | 1,000,000 | GenomeDx Biosciences CorpINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 27, 2026source: clinicaltrials